However, clinical trials in metastatic RCC (mRCC) using GM-CSF as single-agent or combined with either interleukine-2 (IL-2) or interferon-α (IFN-α) have failed to show anti-tumor effect [9–11]. This evidence concerns the gene CSF2 and neoplasm.